8 weeks of 25 g/day of milled chia supplemented-isocaloric diet

Non-Alcoholic Fatty Liver Disease

Dietary Modification

8 weeks of an isocaloric diet supplemented with 25 g/day of milled chia

Milled chia seeds

Chia Supplementation and Non Alcoholic Fatty Liver Disease

Effect of a Chia Supplemented Diet (Salvia Hispanica) on the Cardiometabolic Risk Profile in Patients With NAFLD (Non Alcoholic Fatty Liver Disease)

To assess the effect of 25 g/day of milled chia in 25 patients with NAFLD.Improvement of LSAI (liver spleen attenuation index) measured by computed tomography In a single-arm experimental design study

Increase in Alpha linolenic acid with chia supplemented diet. Measured by gas chromatography.

Improvement of lipid parameters (total colesterol, LDL-C, triglycerides, HDL-C) including free fatty acids

Aida Medina Urrutia

Medical sience investigator

Instituto Nacional de Cardiologia Ignacio Chavez

Of eligible subjects, 45/67 started an intervention program with Ω-3 (CASES). The intervention consisted in supplementation with highly purified Ω-3, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at a dose of 50-60 mg/kg/day for 12 months

Others 22/67 subjects joined to the study as data contributors, and were entered as controls (CONTR).

Type 1 Diabetes Mellitus

Supplementation with Ω-3, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at a dose of 50-60 mg/kg/day for 12 months, currently underway or completed after 12 months of omega-3 administration, in 42/65 T1D children

omega-3 supplementation

Vitamin D supplementation

Pilot Study of OMEGA-3 and Vitamin D in High-Dose in Type I Diabetic Patients (POSEIDON)

Omega-3 and Vitamin D Supplements in Childhood T1D

Omega 3 Long Chain Polyunsaturated Fatty Acids, Enriched Mediterranean Diet and Vitamin D Supplementation in Childhood Type 1 Diabetes: One Year Case-cohort Study

mg/dl; 1 mg/dl:0.05551 mmol/liter; gluco-oxidase colorimetric method (GLUCOFIX, by Menarini Diagnostics, Florence, Italy)

measured through the high-performance liquid chromatography (HPLC), using a Variant machine (Biorad, Hercules, CA); ); intra- and inter-assay coefficients of variation are respectively lower than 0.6% and 1.6%. Linearity is excellent from 3.2% (11 mmol/mol) to 18.3% (177 mmol/mol).

measured by serum 25(OH)D assay, using an immunochemiluminescence (CLIA) method (DiaSorin Liaison® Test, Stillwater MN-USA); the coefficient of inter-individual variability of the method (CVa%) was 10%

AA, EPA, DHA percentages and respective AA/EPA ratio were determined by high-resolution capillary gas chromatography in whole blood using dried blood spots testing

expressed in ng/ml, were measured, on citrate or heparinized plasma, both by chemiluminescent "sandwich" immunoassay (DiaSorin Liaison) and by immunochemiluminescence with automatic analyzer Immulite 2000, Medical Systems with coefficient of variability of 7.40%

a composite index of insulin demand and metabolic control IDAA1c, calculated as HbA1c (%) + 4 insulin dose (UI/kg/24 h), was used. A score <9 meet definition of partial remission and REIS, according with the U.S. Food and Drug Administration, and previous studies in TrialNet

all IPD that underlie results in the publication will be shared

Francesco Cadario, MD

MD Division of Pediatrics

Azienda Ospedaliero Universitaria Maggiore della Carita

University of Eastern Piedmont

A cohort study was performed in 2017, in all T1D patients 1-18 years old with onset in the years 2014-2017. Supplementation with omega3 was proposed to all subjects with onset between 2015-2017. Patients with onset in 2014 were enrolled only as control subjects. The work was performed on retrospectively collected data in medical records for patients with start of the disease in 2014-2016. Patients enrolled since 2017 have been studied prospectively.

Participants will receive fish oil gelcaps that contain 1.6 grams of omega-3 fatty acids (800 mg of EPA, 600 mg DHA, 200 mg other omega-3 fatty acids) for 12 weeks.

Participants will receive 1 gram of oleic sunflower oil for 12 weeks.

Participants will receive fish oil gelcaps that contain 1.6 grams of omega-3 fatty acids (800 mg of EPA, 600 mg DHA, 200 mg other omega-3 fatty acids) for 12 weeks.
Fish oil that contains omega-3 fatty acids: Fish oil gelcaps that contain 800 mg of EPA, 600 mg of DHA, 200 mg other omega-3 fatty acids

Fish Oil

Participants will receive 1 gram of oleic sunflower oil for 12 weeks.
Fish oil that contains omega-3 fatty acids: Fish oil gelcaps that contain 800 mg of EPA, 600 mg of DHA, 200 mg other omega-3 fatty acids

Placebo

Total

Sex: Female, Male

Region of Enrollment

Markers of immune senescence will include change in the expression of the senescence markers CD28 and CD57 on the surface of peripheral CD4+ and CD8+ T lymphocytes. We will measure the percentage of CD4+ and CD8+ T lymphocytes that are CD28-/CD57- or CD28-/CD57+. We will subtract the percentage obtained at Week 12 from the baseline percentage to calculate the change scores.

Change in Markers of Immune Senescence Between Baseline Values and Values After 12 Weeks of Supplementation

Overall Study

Barbara Swanson

HIV Infection

Fish oil gelcaps that contain 800 mg of EPA, 600 mg of DHA, 200 mg other omega-3 fatty acids

Fish oil that contains omega-3 fatty acids

Gelcaps that contain 1 gram of oleic sunflower oil

Rush University Medical Center

Fish Oil for HIV-Related Inflamm-aging and Immune Senescence

Participants were randomized to one of two arms:
Intervention arm = fish oil Control arm = placebo.

All gelcaps were overencapsulated to mask their contents

docosahexaenoic acid/diarreia

Chia Supplementation and Non Alcoholic Fatty Liver Disease

Omega-3 and Vitamin D Supplements in Childhood T1D

Fish Oil for HIV-Related Inflamm-aging and Immune Senescence

O mais completo banco de dados de ervas medicinais apoiado pela ciência